Danicopan MAD study in healthy volunteers

Phase 1, randomised, double-blind trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH) (4 cohorts), sponsored by Alexion Pharmaceuticals. Primary endpoint: Incidence Of Serious Adverse Events, Grade 3 Or 4 Adverse Events, AEs Leading To Discontinuation, And Clinically Significant Laboratory Abnormalities And Electrocardiogram Abnormalities. Started May 2016; status: completed.